BPTH | BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH) Files An 8-K Regulation FD Disclosure – Market Exclusive

BIO-PATH HOLDINGS, INC.(NASDAQ:BPTH) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD Disclosure.On October 22, 2020, Bio-Path Holdings, Inc.(the “Company”) issued a press release titled, “Bio-Path Receives Notice of Allowance for Strategic Patent for Prexigebersen in Combination with Front Line Cytidine Analogues or Bcr-Abl Tyrosine Kinase Inhibitors in a Variety of Cancers.” […]Market Exclusive

BPTH | Bio-Path (NASDAQ:BPTH) Stock Rating Lowered by Zacks Investment Research

Bio-Path (NASDAQ:BPTH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Monday, Zacks.com reports.According to Zacks, “BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical […]Zolmax […]

BPTH | Analysts Anticipate Bio-Path Holdings Inc (NASDAQ:BPTH) to Post -$0.83 Earnings Per Share

Equities research analysts expect Bio-Path Holdings Inc (NASDAQ:BPTH) to post ($0.83) earnings per share for the current fiscal quarter, according to Zacks.Zero analysts have provided estimates for Bio-Path’s earnings.Bio-Path reported earnings of ($0.78) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 6.4%.The firm is […]Transcript Daily